0000000001123818

AUTHOR

C. Ficorella

showing 5 related works from this author

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGenes BRCA2Genes BRCA1Breast NeoplasmsBreast cancerRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAromataseskin and connective tissue diseasesbiologybusiness.industryIncidence (epidemiology)Estrogen AntagonistsHematologymedicine.diseaseClinical trialTamoxifenOncologyChemotherapy AdjuvantRelative riskbiology.proteinHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugAnnals of Oncology
researchProduct

Identification and Characterization of BRCA1 and BRCA2 Founder Mutations

2012

A large number of cancer predisposing BRCA1/BRCA2 mutations have been reported, with a wide variety among populations. In some restricted groups, specific germline mutations in these tumor suppressor genes have been found with high predominance, due to a founder effect. We focused our review on the Italian founder mutations. The first Italian BRCA1 founder mutation, 5083del19, was found in Calabria: the presence of common allele in all carriers of this mutation (also in families with Calabrian origin living in other parts of Italy) confirmed its founder effect. The same BRCA1 mutation was identified in the Sicilian population, but only the haplotype analysis can reveal the common ancestor o…

Settore MED/06 - Oncologia Medicabusiness.industryObstetrics and GynecologyMedicineIdentification (biology)Computational biologyBRCA1; BRCA2; Founder mutationBRCA1Founder mutationbusinessBRCA2Current Women's Health Reviews
researchProduct

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast ca…

2017

Abstract Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Resul…

0301 basic medicineOncologyReceptor ErbB-2chemistry.chemical_compoundErbB-20302 clinical medicineDose-intensityExemestane80 and overNeoplasm MetastasisFulvestrantAged 80 and overeducation.field_of_studyAdvanced breast cancer Dose-intensity Everolimus Fulvestrant Hormone-receptor positiveAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2; SurgeryGeneral MedicineMiddle AgedEverolimu030220 oncology & carcinogenesisAdvanced breast cancerFemaleAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; SurgeryReceptormedicine.drugAdultmedicine.medical_specialtyPopulationSocio-culturaleBreast NeoplasmsHormone-receptor positive03 medical and health sciencesBreast cancerAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2Internal medicinemedicineHumansEverolimusAdverse effecteducationAgedNeoplasm StagingGynecologyEverolimusFulvestrantbusiness.industryfungiCancermedicine.diseaseAndrostadienesClinical trial030104 developmental biologychemistrySurgerybusinessFollow-Up StudiesThe Breast
researchProduct

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

2018

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July …

medicine.medical_specialtySocio-culturaleHormone-receptor positiveExemestane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerElderlyExemestaneWeight lossInternal medicineAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positive; OncologymedicineEverolimus030212 general & internal medicineStomatitisPneumonitisAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positiveEverolimusbusiness.industryCancermedicine.diseaseRashEverolimuchemistryOncology030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAAdvanced breast cancermedicine.symptombusinessResearch Papermedicine.drug
researchProduct

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

2019

Alessio Cortellini,1,2 Katia Cannita,1 Alessandro Parisi,1,2 Paola Lanfiuti Baldi,1 Olga Venditti,1 Carla D’Orazio,1,2 Antonella Dal Mas,3 Giuseppe Calvisi,3 Aldo V Giordano,4 Vincenzo Vicentini,5 Roberto Vicentini,5 Lara Felicioni,6 Antonio Marchetti,7 Fiamma Buttitta,6 Antonio Russo,8 Corrado Ficorella1,2 1Medical Oncology, St Salvatore Hospital, University of L’Aquila, L’Aquila, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 3Department of Pathology, St Salvatore Hospital L’Aquila, L’Aquila, Italy; 4Diagnostic and Interventional Radiology, St Salvatore Hos…

5-fluorouracil infusion; Bevacizumab; Clinical practice; Intensive chemotherapy regimen; Metastatic colorectal cancerintensive chemotherapy regimenmetastatic colorectal cancer intensive chemotherapy regimen bevacizumab clinical practice 5-fluorouracil infusionmetastatic colorectal cancer5-fluorouracil infusionbevacizumabOncoTargets and TherapyOriginal Researchclinical practiceOncoTargets and therapy
researchProduct